FIELD: chemistry.
SUBSTANCE: invention relates to a use of N-(2-thiazolyl)amide derivatives of formula
,
where R1 and R2 are independently selected from H, -NO2, halogen, C1-C6 alkyl with a straight chain, where at least one of R1 and R2 is different from H; m equals 0, 1, 2 or 3; X is selected from a group consisting of: indole of formula (A) bound in position 2, indole of formula (B) bound in position 3 and indazole of formula (C) bound in position 3:
, 
, 
,
where R3 is selected from H and C1-C6 alkyl with a straight chain; R4, R5, R6 and R7 are independently selected from H and C1-C6 alkoxy group; R8 is selected from H and C1-C6 alkyl, or any of its pharmaceutically acceptable salts to obtain a medicinal agent for treating or preventing diseases or conditions mediated by GSK-3, especially neurodegenerative diseases such as Alzheimer's disease or insulin-independent sugar diabetes. The invention also relates to a compound of formula (I), a pharmaceutical composition based on said compound and synthesis method thereof.
EFFECT: high efficiency of using said derivatives.
30 cl, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2450000C2 |
| GSK-3 INHIBITORS | 2005 |
|
RU2379300C2 |
| GSK-3 INHIBITORS | 2006 |
|
RU2449998C2 |
| SELECTIVE BUTYRYLCHOLIN ESTERASE INHIBITORS | 2005 |
|
RU2386627C2 |
| TACRINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS | 2004 |
|
RU2402545C2 |
| HETEROCYCLIC INHIBITORS OF GLYCOGEN SYNTHASE-KINASE GSK-3 | 2001 |
|
RU2294931C2 |
| IMIDAZOLE DERIVATIVES ACTIVE TO CB1 RECEPTOR | 2005 |
|
RU2377238C2 |
| CHEMICAL COMPOUNDS AS INTERLEUKIN-1 INHIBITORS | 2018 |
|
RU2792143C2 |
| AMIDES OF 3-SUBSTITUTED 5- AND 6-AMINOALKYLINDOLE-2-CARBOXYLIC ACID AND RELATED ANALOGUES SUCH AS CASEIN KINASE IΕ INHIBITORS | 2005 |
|
RU2369599C2 |
| PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | 2011 |
|
RU2582338C2 |
